June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Preferential Hyperacuity Perimeter (PHP) in Vitreoretinal Interface Disorders
Author Affiliations & Notes
  • Alessa Crossan
    ophthalmology, medical college of wisconsin, Milwaukee, Wisconsin, United States
  • james kim
    ophthalmology, medical college of wisconsin, Milwaukee, Wisconsin, United States
  • mohamed gendy
    ophthalmology, medical college of wisconsin, Milwaukee, Wisconsin, United States
  • velinka medic
    ophthalmology, medical college of wisconsin, Milwaukee, Wisconsin, United States
  • Krissa Packard
    ophthalmology, medical college of wisconsin, Milwaukee, Wisconsin, United States
  • Dennis P Han
    ophthalmology, medical college of wisconsin, Milwaukee, Wisconsin, United States
  • Judy Kim
    ophthalmology, medical college of wisconsin, Milwaukee, Wisconsin, United States
  • Footnotes
    Commercial Relationships   Alessa Crossan, None; james kim, None; mohamed gendy, None; velinka medic, None; Krissa Packard, None; Dennis Han, None; Judy Kim, NotalVision (F)
  • Footnotes
    Support  Vitreoretinal Surgery Foundation, NotalVision
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3698. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alessa Crossan, james kim, mohamed gendy, velinka medic, Krissa Packard, Dennis P Han, Judy Kim; Preferential Hyperacuity Perimeter (PHP) in Vitreoretinal Interface Disorders. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3698.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Foresee Home (Notal Vision, Israel) machine uses preferential hyperacuity perimetry (PHP) testing to detect metamorphopsia and has been shown in a multicenter clinical trial to detect the onset of exudative age-related macular degeneration (AMD) earlier than with standard care. We assessed its ability to detect metamorphopsia in patients with epiretinal membrane (ERM) before and after surgery in hopes of using Foresee Home as an objective measure of metamorphopsia in these patients.

Methods : This is a prospective study of nine eyes of nine patients undergoing pars plana vitrectomy and membrane stripping for idiopathic ERM. Foresee Home testing was performed prior to surgery as a baseline and at 1 month, 3 months and 6 months after the surgery, with three repetitions at each visit. Inclusion criteria are diagnosis with vitreoretinal interface disorder, 18 years of age or older, BCVA of 20/60 or better, and cognitive and physical ability to use the Foresee Home device. Macular or optic nerve disease, significant media opacity, and BCVA worse than 20/60 were exclusion criteria. The test score, a Foresee Home parameter indicating metamorphopsia, was collected for each subject at each visit before and after their vitrectomy surgery. The map score, a Foresee Home parameter indicating the reliability of the test score, was collected for each subject at each visit before and after surgery. Unpaired t test was used to compare the mean of both parameters before and after.

Results : The average Test Score for the group at each study visit time points was as follows: at baseline= 0.151, at 1 month=0.153, at 3 months=0.134, and at 6 months=0.069. The average Map Score for the group at each time points was as follows: at baseline=0.133, at 1 month = 0.132, at 3 months = 0.207, and at 6 months = 0.126. Unpaired two tailed t-test of the test score of all participants comparing prior and after values was P= 0.61. Unpaired two tailed t-test of the map score of all participants comparing prior and after values was P=0.35.

Conclusions : Foresee Home testing documented metamorphopsia in eyes with idiopathic ERM. No statistically significant difference was seen in Foresee Home test score before and after vitrectomy surgery. Further enrollment may clarify the role of PHP testing in ERM patients.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×